Bob More
Managing Director @ Alta Partners
Seattle, United States
Bob More is a Series A investor at Alta Partners in Seattle focused on Biotechnology and Life Science. Bob More is based out of Cambridge, Massachusetts, and is the Board Director of EGenesis. Bob previously worked at Biotechnology Innovation Organization as Board. Bob More attended Middlebury College.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Bob More invests in
Stages Bob More invests in
Countries Bob More invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (67%)
- Life Science 1 (33%)
- Therapeutics 1 (33%)
Stage
- Series A 2 (67%)
- Series B 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MBrace Therapeutics
|
MBrace Therapeutics is a privately held biopharmaceutical business dedicated to improving cancer patients' quality of life by developing antibody-drug conjugates (ADCs) against novel oncology targets. | $85M / Series B / Nov 14, 2023 | |
|
MBrace Therapeutics
|
MBrace Therapeutics is a privately held biopharmaceutical business dedicated to improving cancer patients' quality of life by developing antibody-drug conjugates (ADCs) against novel oncology targets. | $25M / Series A / Jan 01, 2021 | |
Tyra Biosciences
|
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Tyra is using its proprietary SNÅP platform, which is optimized to enable rapid and precise refinement of structural design through iterative molecular SNÅPshots, in orderto generate next-generation product candidates that are specifically designed to address acquired drug resistance and provide alternative treatment options. Tyra is initially focused on developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor, or FGFR, family, which are altered in approximately 7% of all cancers. Tyra’s lead product candidate, TYRA-300, is designed to selectively inhibit FGFR3, with an initial focus on patients with bladder cancer. | $50M / Series A / Jan 10, 2020 |
Co-Investors
About Alta Partners
Alta Partners is a venture capital firm investing in the healthcare and life sciences sector. Their diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for their companies and their investors.
Alta Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dan Janney
Managing Director
|
|||
Peter Hudson
Managing Director
|
|||
|
Alison de Bord
Director
|
|||
|
Bob More
Managing Director
|
|||
Edward Penhoet
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bob More invest in?
Bob More invests primarily in Biotechnology, Life Science and Therapeutics startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bob More?
Public channels for Bob More include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bob More last invest?
The most recent investment recorded for Bob More closed in Nov 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
